News
DNA
8.10
-1.70%
-0.14
Ginkgo Bioworks, Agricen enter collaboration
TipRanks · 2d ago
Weekly Report: what happened at DNA last week (1208-1212)?
Weekly Report · 4d ago
ProteoNic's 2G UNic Technology Licensed By Ginkgo Bioworks For Use In $22.2M Project Awarded To Ginkgo By Biomedical Advanced Research And Development Authority
Benzinga · 12/11 13:49
Ginkgo Bioworks partners with Deep Origin to develop new drug safety tools
TipRanks · 12/09 13:10
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
PR Newswire · 12/09 13:00
Weekly Report: what happened at DNA last week (1201-1205)?
Weekly Report · 12/08 09:35
Ginkgo Bioworks Shares Rise After 4-Year, $47M Contract
Dow Jones · 12/05 14:51
Ginkgo Bioworks Awarded 4-Yr, Up To $47M Contract By EMSL To Co-Design, Build, And Integrate High‑Throughput Automated Phenotyping Platform In Support Of M2PC
Benzinga · 12/05 13:42
Ginkgo Bioworks awarded four-year, up to $47M contract from EMSL
TipRanks · 12/05 13:40
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
PR Newswire · 12/05 13:33
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
PR Newswire · 12/03 13:00
Weekly Report: what happened at DNA last week (1124-1128)?
Weekly Report · 12/01 09:33
Private Markets: Prediction market platform Kalshi secures $300M
TipRanks · 11/28 15:01
Weekly Report: what happened at DNA last week (1117-1121)?
Weekly Report · 11/24 09:35
Ginkgo Bioworks (DNA): Assessing Valuation Following Major ARPA-H-Backed Phage Therapy Collaboration
Simply Wall St · 11/20 17:31
Ginkgo Bioworks: Scaling Science, Not Revenue
Seeking Alpha · 11/20 17:27
Could Ginkgo Bioworks (DNA) Leverage Academic Ties to Reinforce Its Microbiome Research Edge?
Simply Wall St · 11/19 05:25
Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health
PR Newswire · 11/18 13:00
Why Investors Shouldn't Be Surprised By Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) 39% Share Price Plunge
Simply Wall St · 11/17 10:23
Weekly Report: what happened at DNA last week (1110-1114)?
Weekly Report · 11/17 09:36
More
Webull provides a variety of real-time DNA stock news. You can receive the latest news about Ginkgo Bioworks Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.